Treatment of Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Irritability: Results From the Multimodal Treatment Study of Children With ADHD (MTA)  by Fernández de la Cruz, Lorena et al.
62EW RESEARCHNTreatment of Children With Attention-Deﬁcit/Hyperactivity
Disorder (ADHD) and Irritability: Results From the
Multimodal Treatment Study of Children With ADHD (MTA)
Lorena Fernandez de la Cruz, PhD, Emily Simonoff, MD, James J. McGough, MD,
Jeffrey M. Halperin, PhD, L. Eugene Arnold, MD, MEd, Argyris Stringaris, MD, PhD, MRCPsychObjective: Clinically impairing irritability affects 25% to
45% of children with attention-deﬁcit/hyperactivity dis-
order (ADHD); yet, we know little about what inter-
ventions are effective in treating children with ADHD and
co-occurring irritability. We used data from the Multi-
modal Treatment Study of Children With ADHD (MTA)
to address 3 aims: to establish whether irritability in
children with ADHD can be distinguished from other
symptoms of oppositional deﬁant disorder (ODD); to
examine whether ADHD treatment is effective in treating
irritability; and to examine how irritability inﬂuences
ADHD treatment outcomes.
Method: Secondary analyses of data from the MTA in-
cluded multivariate analyses, and intent-to-treat random-
effects regression models were used.
Results: Irritability was separable from other ODD
symptoms. For treating irritability, systematic stimulant
treatment was superior to behavioral management but not
to routine community care; a combination of stimulantsClinical guidance is available at the end of this article.
Supplemental material cited in this article is available online.
www.jaacap.organd behavioral treatment was superior to community care
and to behavioral treatment alone, but not to medication
alone. Irritability did not moderate the impact of treat-
ment on parent- and teacher-reported ADHD symptoms
in any of the 4 treatment groups.
Conclusion: Treatments targeting ADHD symptoms are
helpful for improving irritability in children with ADHD.
Moreover, irritability does not appear to inﬂuence the
response to treatment of ADHD.
Clinical trial registration information—Multimodal
Treatment Study of Children With Attention Deﬁcit
and Hyperactivity Disorder (MTA); http://www.
clinicaltrials.gov; NCT00000388.
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J Am Acad Child Adolesc Psychiatry 2015;54(1):62–70.linically impairing irritability affects 25% to 45% of
children with attention-deﬁcit/hyperactivity disor-C der (ADHD)1; yet, the evidence base for treatment
selection in the presence of irritability remains thin. This
article addresses this knowledge gap by analyzing data from
the Multimodal Treatment Study of Children With ADHD
(MTA), a large randomized trial comparing various treat-
ment modalities among children with ADHD.2
ADHD is among the most common child psychiatric
disorders worldwide.3 It is deﬁned by chronic, pervasive,
and impairing symptoms of inattention and hyperactivity/
impulsivity.4 Although irritability, deﬁned by temper out-
bursts and proneness to anger,5 is not a diagnostic criterion
for ADHD, it is a common presentation in this clinical
group6,7 and is listed under the associated features of ADHD
in the DSM.4 In an epidemiological study, 38% of children
with ADHD had irritable mood, nearly 10-fold higher overgeneral population rates.8 This raises the question of how
best to treat the subgroup of children with ADHD and
irritability.
One approach to this question is to consider irritability as
one of the manifestations of behavior problems that are
typical of ADHD. Indeed, irritability is characteristic of
children with oppositional deﬁant disorder (ODD), which is
highly comorbid with ADHD.9 Substantial evidence sug-
gests that stimulant treatment also reduces ODD symptoms
in those with ADHD2,10,11 and that parenting interventions
may also be useful.12 However, this is an assumption that
needs to be explicitly tested, as mounting evidence indicates
that irritable mood is distinct from other, typically head-
strong, behaviors characteristic of ODD. This distinction is
reﬂected in the DSM-54 and is based on research showing
that irritability is separable from headstrong behaviors (e.g.,
argumentativeness, noncompliance, and rule breaking) by
virtue of its multivariate structure,13 longitudinal course,14,15
external predictions,16 and genetic associations.17 In partic-
ular, irritability predicts subsequent depression and gener-
alized anxiety, whereas headstrong behaviors predict
subsequent delinquent behaviors.16 If irritability is clinically
and etiologically distinct from other behavior problems, ir-
ritability in ADHD may also require distinct treatment
compared to headstrong behaviors. However, there is littleJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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FIGURE 1 Parent-reported irritability response to multimodal
treatment in the 4 treatment groups. Note: Beh ¼ Behavioral
treatment; CC ¼ Community Comparison; Comb ¼ Combined
treatment; MedMgt ¼ Medication management.
TREATMENT OF ADHD AND IRRITABILITYresearch on the distinctions between these 2 groups of
symptoms in children with ADHD13 or evidence about how
best to treat irritable children who have ADHD.
Here we use data from the MTA to address these ques-
tions by examining 3 aims. First, we wanted to establish the
robustness and clinical relevance of irritability in the MTA.
In particular, it is important to know whether irritability in
children with ADHD can be distinguished from other typical
symptoms of oppositionality, namely, headstrong symptoms.
We hypothesized the following: that irritability would be
separable from headstrong behaviors in multivariate analyses;
that irritability would have different external correlates/
consequences (building upon prior investigations,14 we ex-
pected that irritability would signiﬁcantly differentially
predict internalizing symptoms and disorders such as
depression and anxiety, whereas the headstrong dimension
would differentially predict conduct problems, such as
conduct disorder [CD]); that irritability would show sufﬁ-
cient longitudinal continuity in children with ADHD such
that it could be differentiated from headstrong symptoms;
and that irritable and headstrong behaviors each would
contribute independently to impairment.
Our second aim was to ascertain how irritability in
ADHD responds to treatment with stimulants and/or
behavioral therapy. Clinical experience and prior results
from randomized controlled treatment studies in chil-
dren18-20 suggest that stimulant treatment may be useful to
treat irritability in ADHD and should be considered as a
ﬁrst-line treatment1; however, the evidence is somewhat
mixed. Two randomized controlled trials comparing
amphetamine and placebo found no beneﬁcial effect of the
medication on a broad range of emotional problems, and
some studies have found that amphetamine preparations
increase irritability and lability.21 On the other hand, it has
recently been shown that children with ADHD and behavior
problems that are closely linked to irritability probably
respond to behavioral treatment.22,23 Similarly, a recent
meta-analysis of randomized controlled trials12 has provided
evidence from blinded outcomes that behavioral in-
terventions improve parenting and reduce childhood
conduct problems in ADHD. To address this matter, we
examine 2 competing hypotheses: 1 hypothesis based on the
preliminary ﬁndings above that suggest stimulant treatment
could be helpful; and the other hypothesis, which is that
because irritability can be a component of behavior problems
such as ODD, it may respond well to behavioral treatment.
The third aim was to establish whether the response to
treatment of children with ADHD and irritability differed
from that of children without irritability. There is surpris-
ingly little research in this area, although a previous study
using MTA data indicated that symptoms of mania do not
inﬂuence the treatment response to methylphenidate or its
side effect proﬁle in children with ADHD.24 However, this
investigation used the 1-month methylphenidate titration
trial subset of the MTA and therefore did not include the
comparisons with the behavioral interventions nor the
treatment outcome after 14 months. A subsequent study by
Galanter and colleagues, also using MTA data, showed that
children with manic symptoms, as deﬁned using the ChildJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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more morbidity at study onset, yet they also responded to
standard ADHD treatment without suffering more side ef-
fects compared to children without manic symptoms.25 This
suggests that standard treatment may beneﬁt severely
affected children with ADHD; however, the inclusion of
anxiety/depression, aggression, and attention in the deﬁni-
tion of manic symptoms makes it difﬁcult to estimate the
effects of treatment on irritability and on how the presence of
irritability may moderate treatment response in children
with ADHD. This is particularly important given the sepa-
rability of irritability from other behavior problems. Hence,
in this study, we tested whether the response to MTA
treatments, including medication, behavioral treatment, and
the combination, varied according to the level of irritability.
Our expectation was that while irritable children would
show higher levels of ADHD symptoms, they would
respond similarly to children low on irritability. In partic-
ular, we expect that the previously demonstrated superiority
of the medication management over the community com-
parison and the behavioral treatment arms in the MTA2
would remain even when accounting for levels of irritability.
METHOD
Participants and Procedure
A total of 579 children meeting diagnostic criteria for ADHD
Combined Type were recruited from 6 different US sites and
randomly assigned to 1 of the following 4 groups: medication
management (“MedMgt”; n ¼ 144; 24.9%); behavioral treatment
(“Beh”; n ¼ 144; 24.9%); combined treatment (“Comb”; n ¼ 145;
25.0%); or treatment-as-usual community comparison (“CC”; n ¼
146; 25.2%). The ﬁrst 3 groups were treated for 14 months in spec-
iﬁed protocols. Brieﬂy, MedMgt consisted of a 1-month double-blind
titration with methylphenidate for best dose, progressing to an open
titration with other drugs, such as d-amphetamine, pemoline, or
imipramine if methylphenidate was unsatisfactory. Beh consisted of
intense, multi-component individual and group parent training;
teacher consultation; a child-directed, 8-week, full-time summer
treatment program; and use of a 12-week, half-time classroom
behavioral specialist. Comb integrated the MedMgt and Beh stra-
tegies, with more extensive assistance from the behavioral therapistwww.jaacap.org 63
FERNANDEZ DE LA CRUZ et al.to assist in medication adjustment and information from the phar-
macotherapist to aid in decision making about escalation of
behavioral interventions. The fourth group (CC) was referred for
community treatment of the parents’ choosing. The mean age of the
children at baseline was 8.5 years (SD ¼ 0.8 years, range ¼ 7–10
years), and 114 children were female (19.7%). Ethnic composition of
the sample included 60.8% of white ethnicity, 19.9% African
American, and 19.3% Hispanic, racially mixed, or from other ethnic
origins. Treatment groups did not differ signiﬁcantly at baseline on
gender, ethnicity, IQ, comorbidity, Conners Parent and Teacher
Rating Scales scores, impairment, and medication for ADHD before
the study. The only signiﬁcant difference was age, although all
participants were actually in a tight age range (the youngest were in
the behavioral treatment group: mean age ¼ 8.3 years; and the
oldest were in the medication management group: mean age ¼ 8.6
years). At least 1 parent and all participants in the original MTA
study provided written permission and assent for participation
before initiation of any study procedures as approved by each site’s
institutional review board. For the present study, all of the partici-
pants from the original study were included. Additional details
about the sampling and the procedures in the MTA have been
widely described elsewhere.2,26,27Measures
The measures relevant to our study are described below. A
comprehensive description of the assessment measures used in the
MTA has been described elsewhere.2,28
ADHD symptom severity was measured by using the mean
score of items 1 to 18 of the parent- and the teacher-reported
Swanson, Nolan, and Pelham (SNAP) rating scale,29 which includes
the inattention and hyperactivity/impulsivity subscales.
In accordance with previous studies,14,30 a measure of irritability
was generated by adding up the following 3 ODD items on the
parent-reported SNAP: “Loses temper”; “Is touchy or easily
annoyed by others”; and “Is angry and resentful.” The scores ranged
from 0 to 9. In addition, a categorical irritability outcome was
generated using a median split into high and low irritability and was
used for purposes of illustration in several ﬁgures. The irritabilityTABLE 1 Irritability Response to Attention-Deficit/Hyperactivity Dis
Irritabil
Baseline
3-Month
Assessment
9-
Ass
Treatment Group Mean SD Mean SD Mean
Community comparison 4.40 2.43 3.77 2.53 3.83
Medication management 4.40 2.65 2.81 2.37 2.75
Behavioral treatment 4.11 2.44 3.39 2.31 3.25
Combined treatment 4.26 2.41 3.02 2.05 2.64
Treatment Group Comparison
Medication management vs. Community comparison
Behavioral treatment vs. Community comparison
Combined treatment vs. Community comparison
Medication management vs. Behavioral treatment
Combined treatment vs. Medication management
Combined treatment vs. Behavioral treatment
Note: SNAP ¼ Swanson, Nolan, and Pelham rating scale.
64 www.jaacap.orgmeasure was based on parent-report, given that parents, as
compared to teachers, are rated as more useful informants of chil-
dren’s emotional problems.31,32
A headstrong dimension was generated by adding up 4 ODD
items on the parent-reported SNAP: “Argues with adults,”
“Actively deﬁes or refuses adult requests or rules,” “Does things
deliberately that annoy other people,” and “Blames others for his or
her mistakes or misbehavior.” The scores ranged from 0 to 12. The
only ODD item not used for either the irritability or the headstrong
scales was “Is spiteful or vindictive.”
The CBCL was used to assess general psychopathology. The
CBCL is a parent-report checklist mapping onto multiple aspects of
psychopathology over a 6-month period.33 Children’s global
impairment was measured by using the Columbia Impairment
Scale–Parent Version (CISP) questionnaire.34Data Analysis
Data analyses for each speciﬁc aim were as follows: 1) To establish
whether irritability was independent from other ODD symptoms in
the MTA sample, we proceeded in 4 ways. First, we explored dif-
ferences in the multivariate structure using a conﬁrmatory factor
analysis (CFA) comparing 2 models (1 versus 2 factors, namely ir-
ritability and headstrong behaviors). Second, we explored the lon-
gitudinal continuity of each measure (irritability and headstrong
behaviors) using path analysis. Third, we explored whether irrita-
bility and headstrong behaviors had different correlates in linear
regression models in which the 2 variables were introduced as
predictors, Finally, we ran a linear regression in which irritability
and headstrong behaviors were predictors of impairment to test
whether the 2 dimensions contributed independently to it. This is
important because impairment can be independent of symptom
severity.35 Signiﬁcant differences between estimates were judged
based on nonoverlapping 95% CI. 2) To test the hypothesis that
MedMgt would be superior to Beh in treating irritability, we ran an
intent-to-treat (ITT) random-effects regression analysis similar to the
original primary analyses but with irritability as the outcome, and
time (including baseline, 3-month, 9-month, and 14-month assess-
ments) and treatment group as predictors, as well as the interactionorder (ADHD) Treatment in the 4 Treatment Groups
ity Scores (SNAP Parent Report)
Month
essment
14-Month
Assessment
Within-Group Effect Size
(Baseline to 14-Month Assessment)SD Mean SD
2.56 3.28 2.18 0.48
2.26 2.80 2.39 0.63
2.20 3.11 2.41 0.42
2.08 2.35 2.22 0.82
Between-Group Effect Size
(Baseline to 14-Month Assessment)
0.20
0.05
0.34
.24
.13
0.38
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TREATMENT OF ADHD AND IRRITABILITYtimetreatment group. As in the original MTA study, we also tested
for site differences and site-by-treatment effects using the interaction
sitetreatment group. In statistical terms, our hypothesis was that
therewould be a signiﬁcant time-by-treatment group interaction, and
that by decomposing this interactionwewould ﬁnd that theMedMgt
group (as well as the Comb) would be superior to the Beh group. In
addition, we calculated the pre–post effect size of each treatment
option by using Cohen’s d formula (mean score baseline–mean score
at 14 months) / pooled SD. 3) Finally, we tested whether baseline
irritability would moderate treatment outcomes, by running an ITT
random-effects regression analysis with the severity of the ADHD
symptoms as the outcome and, again, time (including baseline, 3-
month, 9-month, and 14-month assessments), treatment group, and
site as predictors, as well as the interactions irritabilitytime, irri-
tabilitytreatment group, timetreatment group, sitetreatment
group, and irritabilitytimetreatment group. We also tested
whether irritability would differentially affect the response to in-
dividual treatments by testing the 3-way interaction of irrita-
bilitytreatment grouptime.
Ethical Approval
The de-identiﬁed MTA dataset (MTA96, Version #1) was pro-
vided by the National Institute of Mental Health (NIMH) upon
public-access request. The Psychiatry, Nursing, and Midwifery
Research Ethics Subcommittee (PNM RESC) at King’s College
London approved the secondary analysis of these data (reference
PNM/13/14-34).
RESULTS
The mean score for the whole sample for the parent-reported
irritability subscale derived from the ODD items of the
SNAP was 4.30 (SD ¼ 2.48) and the median value was 4.
Internal consistency was high (Cronbach’s a ¼ .83), and it
showed good convergent validity by correlating highly with
a scale comprising irritability items from the CBCL (Pear-
son’s correlation r ¼ 0.66, latent correlation r ¼ 0.72). This
measure of irritability derived from the CBCL has also been
used in previous research.17 The mean score for the whole
sample for the parent-reported headstrong behaviors sub-
scale derived from the ODD items of the SNAP was 6.44
(SD ¼ 3.19), and the median value was 7. This variable also
showed high internal consistency (Cronbach’s a ¼ 0.83). AtTABLE 2 Irritability Response to Attention-Deficit/Hyperactivity Dis
Outcome: Parent-Reported Irritability c2
Omnibus Tests
Time 44.52
Treatment Group 1.38
TimeTreatment Group 33.66
Decomposing TimeTreatment Group Interaction
CC vs. MedMgt —
CC vs. Beh —
CC vs. Comb —
MedMgt vs. Beh —
MedMgt vs. Comb —
Beh vs. Comb —
Note: Significant results are shown in boldface. Beh ¼ behavioral treatment; CC ¼
management.
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symptoms (r ¼ 0.34; p < .001) and with the CISP (r ¼ 0.45;
p < .001) were in the medium range.
Aim I: To Establish the Independence of the Irritability
Dimension in the MTA Sample
The 2-factor model (irritability versus headstrong behaviors)
showed a better ﬁt with the data (AIC ¼ 8,640.38; BIC ¼
8,765.94) compared to the 1-factor model (AIC ¼ 8,751.85;
BIC ¼ 8,873.08), as conﬁrmed by difference testing (value ¼
69.23, df ¼ 1; p  .001).
Also, the within-domain stability was signiﬁcantly
stronger than the across-domain stability: irritability at
baseline was a better predictor of irritability at 14 months
(b ¼ 0.52 [95% CI ¼ 0.42–0.61]; p  .001) compared to
headstrong behaviors at 14 months (b¼ 0.15 [95% CI¼ 0.05–
0.25]; p ¼ .004), whereas the headstrong behaviors dimen-
sion at baseline was a signiﬁcantly better predictor of
headstrong behaviors at 14 months (b ¼ 0.43 [95% CI ¼
0.33.52]; p  .001) than irritability at 14 months (b ¼ 0.05
[95% CI ¼ 0.06–0.15]; p ¼ .366). This supports the idea that
these constructs are distinct from each other (for more details
on the path analytical model, see Figure S1, available online).
Irritability was a signiﬁcantly stronger predictor than
headstrong behaviors for the Internalizing Scale at baseline
(irritability: b ¼ 0.43 [95% CI ¼ 0.32–0.54] versus head-
strong behaviors: b ¼ 0.06 [95% CI ¼ –0.04–0.17]) as well
as at the end of treatment (irritability: b ¼ 0.35 [95%
CI ¼ 0.23–0.47] versus headstrong behaviors: b ¼ 0.03
[95% CI ¼ –0.15–0.08]). Conversely, the headstrong behav-
iors measure was a signiﬁcantly stronger predictor of the
Externalizing Scale at baseline (irritability: b ¼ 0.29 [95%
CI ¼ 0.21–0.38] versus headstrong behaviors: b ¼ 0.47 [95%
CI ¼ 0.38–0.55]) but not at the end of treatment (irritability:
b ¼ 0.22 [95% CI ¼ 0.10–0.33] versus headstrong behaviors:
b ¼ 0.29 [95% CI¼ 0.18–0.40]) (see Table S1, available online,
for more details).
Finally, irritability and headstrong behaviors each
contributed independently to impairment (irritability:
b ¼ 0.24, p < .001; headstrong behaviors: b ¼ 0.30, p  .001).order Treatment
Coefﬁcient CI P
— — .000
— — .711
— — .000
0.42 (0.92 to 0.07) .095
0.16 (0.33 to 0.65) .515
0.71 (1.20 to 0.22) .004
0.58 (0.09 to 1.01) .021
0.29 (0.78 to 0.20) .249
0.87 (0.39 to 1.36) .000
community comparison; Comb ¼ combined treatment; MedMgt ¼ Medication
www.jaacap.org 65
FIGURE 2 Changes in parent-reported attention-deficit/
hyperactivity disorder (ADHD) scores in the 4 treatment groups
in individuals with high (a) and low (b) irritability. Note: The
categorical outcome was generated using a median split into
high and low irritability and is used in this figure for purposes
of illustration. However, a dimensional irritability variable
is used in the statistical models presented in the text. Beh ¼
behavioral treatment; CC ¼ community comparison; Comb ¼
combined treatment; MedMgt ¼ Medication management.
FERNANDEZ DE LA CRUZ et al.Aim II: To Test Whether ADHD Treatments Are Effective
at Treating Irritability
There were no differences in the level of parent-reported
irritability at baseline in the 4 treatment groups (F ¼ 0.43,
df ¼ 3, p ¼ .729). As shown in Figure 1, overall, irritability
scores decreased over the course of the treatment. Means
and standard deviations at baseline and at 14 months, as
well as pre–post effect sizes for each treatment arm, can be
found in Table 1. The highest effect size corresponded to
combined treatment (0.82), followed by medication man-
agement (0.63), community comparison (0.48), and behav-
ioral treatment (0.42).
The random-effects regression model included time,
treatment group, and site as predictors of change in irrita-
bility. Omnibus Wald tests for the effect of site did not reach
signiﬁcance (site: c2 [5] ¼ 10.61, p ¼ .060; sitetreatment: c2
[15] ¼ 18.84; p ¼ .221); the variable was therefore excluded in
a subsequent, more parsimonious model, which included
time and treatment group only as predictors of change
(Table 2). Effects of time were signiﬁcant, indicating that
irritability scores decreased signiﬁcantly over time. Effects of
treatment group did not reach signiﬁcance, indicating that
irritability scores in the 4 groups were not signiﬁcantly
different across groups. The interaction time
treatment group was signiﬁcant, indicating that irritability
scores changed differentially according to treatment groups.
Decomposition of this interaction (Table 2) indicated that
from the baseline to the end of the treatment (14-month
assessment), the MedMgt group were more likely to
improve than Beh (coefﬁcient ¼ 0.58; p ¼ .021), but not the
CC group (coefﬁcient ¼ 0.42; p ¼ .095). Those in the Comb
group were more likely to improve than those in the Beh
(coefﬁcient ¼ 0.87; p ¼ .000) and CC (coefﬁcient ¼ 0.71;
p ¼ .004) groups, but there was no difference between the
MedMgt only and Comb (coefﬁcient ¼ 0.29; p ¼ .249). It is
important to note that the effect sizes of difference between
treatments are more modest compared to the effect sizes
between pre- and posttreatment for each group. For
example, the effect size of the difference between the Comb
and CC arms is 0.34, whereas the difference between CC and
Beh is 0.05. However, it is worth noting that the magnitude
of the difference between ADHD treatments is best
accounted for by the random-effects regression model
which, unlike the effect sizes, takes into account the het-
erogeneity across individuals in their responses over time.
Effect sizes are displayed in Table 1.Aim III: To Test Whether Irritability Moderates Treatment
Response of Children With ADHD
Irritability (displayed in Figure 2 as a categorical variable
using a median split into high and low irritability for illus-
tration but analyzed dimensionally) did not have a differ-
ential effect on the reduction in parent-reported ADHD
symptoms across the treatment groups across time. Using
the dimensional irritability variable, we formally tested this
in a random-effects regression model that included base-
line irritability, treatment group, time, and site, with
the interactions irritabilitytime, irritabilitytreatment,66 www.jaacap.orgtimetreatment, and sitetreatment (Table 3). Omnibus
Wald tests for the effect of site did not reach signiﬁcance
(site: c2 [5] ¼ 8.29, p ¼ .141; sitetreatment: c2 [15] ¼ 14.15;
p ¼ .514), for which the variable was excluded in a subse-
quent, more parsimonious model, which included time,
treatment group, and irritability only as predictors of change
(Table 3). In addition, we estimated a 3-way interaction
model including timetreatment groupirritability for
ADHD symptoms as the outcome. As expected, results of
the 3-way interaction were not signiﬁcant (coefﬁcients
ranging from 0.02 to 0.01; p values ranging from .481 to
.898; full results of this model are presented in Table S2,
available online). Moreover, the ﬁrst, more simpliﬁed model
also presented a better ﬁt compared to the model including
the 3-way interaction (AIC ¼ 2924.95 versus 2938.69; BIC ¼
3064.30 versus 3128.21, respectively).
There was a signiﬁcant main effect of irritability (reﬂect-
ing the higher baseline scores of ADHD symptoms in chil-
dren with high baseline irritability) and a main effect of time
(indicating that ADHD scores decreased signiﬁcantly over
time). The effect of site (but not of the interaction
sitetreatment) was also signiﬁcant. As shown in Table 3,JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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TABLE 3 Attention-Deficit/Hyperactivity Disorder (ADHD) Response to Multimodal Treatments Including Baseline Irritability
as a Factor
Outcome: Parent-Reported ADHD c2 Coefﬁcient CI p
Omnibus Tests
Time 57.90 — — .000
Treatment Group 0.19 — — .979
Irritability 21.06 — — .000
TimeTreatment Group 123.41 — — .000
TimeIrritability 7.50 — — .058
IrritabilityTreatment Group 0.16 — — .984
Decomposing TimeTreatment Group Interaction
CC vs. MedMgt — L0.40 (L0.54 to L0.25) .000
CC vs. Beh — L0.03 (0.17 to 0.11) .681
CC vs. Comb — L0.50 (L0.65 to L0.36) .000
MedMgt vs. Beh — 0.37 (0.22 to 0.51) .000
MedMgt vs. Comb — L0.11 (0.25 to 0.03) .136
Beh vs. Comb — 0.48 (0.33 to 0.62) .000
Outcome: Teacher-Reported ADHD c2 Coefﬁcient CI p
Omnibus Tests
Time 87.06 — — .000
Treatment Group 1.17 — — .620
Irritability 1.05 — — .305
TimeTreatment Group 70.13 — — .000
TimeIrritability 3.10 — — .377
IrritabilityTreatment Group 1.65 — — .648
Decomposing TimeTreatment Group Interaction
CC vs. MedMgt — L0.47 (L0.65 to L0.29) .000
CC vs. Beh — 0.14 (0.32 to 0.04) .125
CC vs. Comb — L0.35 (L0.53 to L0.18) .000
MedMgt vs. Beh — 0.33 (0.15 to 0.51) .000
MedMgt vs. Comb — 0.12 (0.06 to 0.30) .204
Beh vs. Comb — 0.21 (0.03 to 0.39) .022
Note: Significant results are shown in boldface. Beh ¼ behavioral treatment; CC ¼ community comparison; Comb ¼ combined treatment; MedMgt ¼
Medication management.
TREATMENT OF ADHD AND IRRITABILITYthe interaction treatmenttime reached signiﬁcance.
Decomposition of this interaction showed a better response
to treatment for children in the MedMgt and Comb arms
compared to those in CC or Beh groups, the same as in the
original ITT report.2
Additional analyses looked at teacher-rated ADHD as an
outcome in the previous model. This was to ensure that the
paper’s main ﬁndings held across informant sources, but
also because teachers were more likely to be blinded to the
treatment condition. As in the case of the parent-rated
ADHD, the variable site did not reach signiﬁcance (site: c2
[5] ¼ 5.33, p ¼ .377; sitetreatment: c2 [15] ¼ 12.54; p ¼ .638)
and therefore was dropped from the model. As can be seen
in the lower part of Table 3, results were very similar to
those using the parent-rated ADHD as an outcome, except
for the fact that the main effect of irritability did not reach
signiﬁcance in this case. As in the case of the parent-reported
ADHD, results of the 3-way interaction timetreatment
groupirritability were not signiﬁcant for the teacher report
(see Table S3, available online).JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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This study used the MTA data to examine irritability in
children with ADHD and its response to different treat-
ments. Our ﬁndings were in line with our initial hypothesis
that, in children with ADHD, irritability is a separable
dimension within the ODD construct. A number of previous
studies converge in showing that oppositionality is best
thought of as comprising 2 (irritable and headstrong)17,36 or
3 (irritable, headstrong, and hurtful)14-16,37 dimensions with
distinct correlates. We did not have enough items to
examine the hurtful dimension in this study, although a
previous study suggests that this does exist in children
with ADHD.38 Consistent with previous studies, irritabil-
ity in this sample contributed to impairment, was more
associated with emotional than conduct problems, and
showed longitudinal continuity. Thus, irritability in ADHD
has the same pattern of multivariate structure and corre-
lates as in children without ADHD. This lends support to
the notion that, instead of irritability being an ADHD-
speciﬁc phenomenon, it is a dimension that cuts acrosswww.jaacap.org 67
Clinical Guidance
 Irritability is a separable dimension within the ODD
construct in children with ADHD.
 Standard ADHD treatments are helpful for reducing
irritability in children with ADHD.
 Irritability symptoms do not seem to inﬂuence ADHD
treatment outcomes. Clinicians can proceed with
conﬁdence that ADHD treatments will be effective even in
the presence of irritability.
FERNANDEZ DE LA CRUZ et al.psychopathology in the manner of the Research Domain
Criteria (RDoC) conceptualization.39 However, further
studies will be required to determine whether the etiolog-
ical mechanisms underlying irritability differ between in-
dividuals with and without ADHD.
Our second aim was to test the hypothesis that symptoms
of irritability would diminish with medication. We found
that irritability levels decreased in all treatment arms after 14
months. However, the magnitude of the effect sizes for the
irritability response to treatment was approximately half of
the magnitude for ADHD symptoms in the original study.2
In support of our hypothesis, MedMgt was signiﬁcantly
better in reducing irritability than Beh treatment. Surpris-
ingly, MedMgt was not signiﬁcantly better than CC in
reducing irritability (p ¼ .095). However, combining
MedMgt with Beh treatment was superior to both the Beh
treatment alone and the CC intervention, but not compared
to MedMgt alone. Beh treatment was not signiﬁcantly
different from the community care intervention. These re-
sults show a partial overlap with previous MTA ﬁndings
regarding other disruptive symptoms. Jensen et al.40
analyzed the response to treatment of oppositional and
aggressive behaviors and found that not only the combined
treatment, but also MedMgt and Beh treatments alone, were
each superior to the CC intervention. Moreover, in that
study there were no differences among the 3 active treat-
ments for oppositional/aggressive symptoms except for the
fact that the Comb was superior to the Beh intervention.40
This treatment response difference between irritable and
oppositional/aggressive behaviors further suggests that it is
important to distinguish between these domains. In light of
our ﬁndings, it is a possibility that, in the case of irritability,
combining medication with behavioral treatment confers
advantages given the superiority of the combination, but not
MedMgt alone, over the CC, although our results did not
actually show superiority of the Comb over MedMgt. Also,
our study results indicate that not all irritability remits after
standard treatment. Whether adjunct treatments, for
example those that have been shown to be effective in
treating aggression in ADHD,41 should be considered for
irritability remains to be established.
Finally, we wanted to examine whether high levels of
irritability diminished ADHD treatment response. We found
that the combined and medication-only treatment arms were
superior to the behavioral treatment and the community
care interventions at reducing ADHD symptoms, regardless
of the level of irritability. This is in keeping with previous
reports on the MTA data showing that the comorbidity of
ADHD with ODD or CD rarely interacted with treatment
response or outcomes.10,42
Limitations of this study include the fact that the MTA
was not originally designed to examine irritability in chil-
dren with ADHD, and therefore patient randomization was
not stratiﬁed by irritability status. Second, the parents in the
MTA study were not blinded to treatment group assign-
ments. As such, the extent to which differential outcomes as
a function of treatment group were inﬂuenced by parental
expectations cannot be determined. However, teacher re-
ports of ADHD symptoms were also used as outcomes, and68 www.jaacap.orgthe results were similar to those obtained when using the
parent reports. Therefore, considering that teachers were
probably blinded (i.e., unlikely to be aware of the treatment
allocation),23 it is unlikely that parental expectations played
a relevant role in the teacher-rated results, although it is
possible that parental expectations affected the child’s
behavior in a way that carried over into school. Third, it may
well be that we were underpowered to detect a 3-way
interaction (irritabilitytimetreatment group) in our
models. However, based on previous simulation results, we
have estimated that the sample size required to detect dif-
ferences among the groups in such a 3-way interaction
would be more than 7,000 participants, which is unrealistic
for most clinical trials.43,44 On the other hand, it is reassuring
that the graphs shown in Figure 2 did not suggest the
presence of this interaction, and if the moderating effect is so
small, it is unlikely to be clinically meaningful. Finally, it is
worth noting that the community care arm in the MTA
study presented with high medication levels (>70% of chil-
dren were taking medication for ADHD, albeit with much
less consistency/monitoring and lower dosing than the
MTA-medicated children) and therefore comparisons
against this group should be interpreted with caution.
These results have 2 important clinical implications. First,
stimulants—a commonly used and relatively safe class of
drugs for ADHD—are also helpful for improving irritability
in children with ADHD. Moreover, the combination of
stimulants and behavioral treatment could help reduce these
symptoms further. Second, irritability symptoms did not
have a negative effect on ADHD treatment outcomes. Cli-
nicians can proceed with conﬁdence that ADHD treatments
will be effective even in the presence of irritability. These 2
aspects had not been demonstrated in major randomized
controlled trials in the ﬁeld and have long remained an area
of clinical uncertainty. Our results may also have etiological
implications. Based on the fact that irritability improves with
treatments that are effective for ADHD symptoms, it would
be tempting to assume that common pathophysiology un-
derlies the overlap between irritability and ADHD. Further
research should therefore explore this possibility. Also,
future studies should investigate whether ADHD treatment
in children with irritable symptoms has a beneﬁcial impact
on mood symptoms in the medium-to-long term, given the
links between irritability and mood disorders.45 &JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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TABLE S1 Linear Regressions With the Irritability and Headstrong Dimensions as Predictors and the Child Behavior Checklist (CBCL) Subscales as Outcomes
Outcome
Predictors
Irritability Dimension Headstrong Dimension
Coefﬁcient 95% CI
Difference Between
Predictors (p)
CBCL
Subscales b 95% CI p b 95% CI p
Withdrawn Baseline 0.32 (0.21 to 0.43) .009 0.04 (0.07 to 0.16) .438 L0.27 (L0.48 to 0.07) .009
14 mo 0.25 (0.13 to 0.37) .027 0.00 (0.12 to 0.12) .958 L0.25 (L0.48 to 0.03) .027
Somatic Complaints Baseline 0.16 (0.04 to 0.27) .678 0.11 (0.00 to 0.23) .059 0.04 (0.26 to 0.17) .678
14 mo 0.18 (0.06 to 0.31) .087 0.01 (0.14 to 0.11) .807 0.20 (0.43 to 0.03) .087
Anxious/Depressed Baseline 0.49 (0.38 to 0.59) .000 0.01 (0.09 to 0.11) .841 L0.48 (L0.66 to L0.28) .000
14 mo 0.38 (0.26 to 0.50) .000 0.05 (0.17 to 0.07) .405 L0.43 (L0.65 to 0.21) .000
Social Problems Baseline 0.17 (0.06 to 0.28) .652 0.22 (0.11 to 0.33) .000 0.05 (0.15 to 0.25) .652
14 mo 0.12 (0.00 to 0.24) .604 0.06 (0.06 to 0.18) .348 0.06 (0.29 to 0.17) .604
Thought Problems Baseline 0.18 (0.07 to 0.30) .484 0.11 (0.01 to 0.22) .071 0.08 (0.29 to 0.14) .484
14 mo 0.10 (0.02 to 0.22) .718 0.06 (0.06 to 0.18) .335 0.04 (0.27 to 0.18) .718
Attention Problems Baseline 0.19 (0.07 to 0.30) .603 0.13 (0.02 to 0.24) .024 0.05 (0.26 to 0.15) .603
14 mo 0.15 (0.03 to 0.28) .202 0.01 (0.12 to 0.13) .912 0.15 (0.38 to 0.08) .202
Delinquent Behavior Baseline 0.10 (0.00 to 0.20) .000 0.44 (0.34 to 0.54) .000 0.34 (0.16 to 0.53) .000
14 mo 0.10 (0.01 to 0.22) .100 0.28 (0.17 to 0.40) .000 0.18 (0.03 to 0.39) .100
Aggressive Behavior Baseline 0.34 (0.25 to 0.42) .274 0.42 (0.34 to 0.51) .000 0.08 (0.07 to 0.24) .274
14 mo 0.24 (0.12 to 0.35) .738 0.27 (0.16 to 0.38) .000 0.03 (0.17 to 0.24) .738
Sex Problems Baseline 0.06 (0.06 to 0.30) .289 0.18 (0.06 to 0.30) .003 0.12 (0.10 to 0.33) .289
14 mo 0.03 (0.09 to 0.15) .617 0.09 (0.03 to 0.21) .139 0.06 (0.17 to 0.27) .617
Internalizing Scalea Baseline 0.43 (0.32 to 0.54) .000 0.06 (0.04 to 0.17) .244 0.37 (L0.56 to L0.17) .000
14 mo 0.35 (0.23 to 0.47) .001 0.03 (0.15 to 0.08) .575 L0.39 (L0.61 to L0.17) .001
Externalizing Scalea Baseline 0.29 (0.21 to 0.38) .026 0.47 (0.38 to 0.55) .000 0.17 (0.02 to 0.32) .026
14 mo 0.22 (0.10 to 0.33) .456 0.29 (0.18 to 0.40) .000 0.07 (0.13 to 0.28) .456
Total Score Baseline 0.35 (0.26 to 0.44) .802 0.33 (0.23 to 0.42) .000 0.02 (0.19 to 0.15) .802
14 mo 0.28 (0.16 to 0.39) .199 0.14 (0.02 to 0.25) .020 0.14 (0.35 to 0.07) .199
Note: Significant results are shown in boldface.
aThe Internalizing Scale is composed of the subscales Withdrawn, Somatic Complaints, and Anxious/Depressed Behavior. The Externalizing Scale is composed of the Delinquent Behavior and Aggressive Behavior
scales.
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TABLE S2 Parent-Reported Attention-Deficit/Hyperactivity Disorder (ADHD) Response to Multimodal Treatments Including Baseline
Irritability as a Factor (3-Way Interaction Model: IrritabilityTimeTreatment Group)
Outcome: Parent-Reported ADHD c2 Coefﬁcient CI p
Omnibus Tests
Time 30.54 — — .000
Treatment Group 0.43 — — .934
Irritability 11.53 — — .001
TimeTreatment Group 20.51 — — .015
TimeIrritability 1.45 — — .695
IrritabilityTreatment Group 0.90 — — .825
TimeIrritabilityTreatment Group 4.27 — — .893
Decomposing TimeTreatment Group Interaction
CC vs. MedMgt — L0.38 (L0.67 to L0.09) .011
CC vs. Beh — 0.01 (0.28 to 0.29) .969
CC vs. Comb — L0.41 (L0.71 to L0.12) .006
MedMgt vs. Beh — 0.43 (0.14 to 0.74) .004
MedMgt vs. Comb — 0.06 (0.25 to 0.37) .702
Beh vs. Comb — 0.38 (0.07 to 0.69) .016
Decomposing IrritabilityTimeTreatment Group
Interaction
CC vs. MedMgt — 0.00 (0.06 to 0.05) .877
CC vs. Beh — 0.01 (0.07 to 0.05) .784
CC vs. Comb — 0.02 (0.08 to 0.04) .481
MedMgt vs. Beh — 0.00 (0.06 to 0.05) .898
MedMgt vs. Comb — 0.02 (0.07 to 0.04) .567
Beh vs. Comb — 0.01 (0.05 to 0.07) .663
Note: Significant results are shown in boldface. Beh ¼ behavioral treatment; CC ¼ community comparison; Comb ¼ combined treatment; MedMgt ¼ medication
management.
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TABLE S3 Teacher-Reported Attention-Deficit/Hyperactivity Disorder (ADHD) Response to Multimodal Treatments Including
Baseline Irritability as a Factor (3-Way Interaction Model: IrritabilityTimeTreatment Group)
Outcome: Teacher-Reported ADHD c2 Coefﬁcient CI p
Omnibus Tests
Time 39.91 — — .000
Treatment Group 2.38 — — .497
Irritability 1.12 — — .291
TimeTreatment Group 15.84 — — .070
TimeIrritability 2.11 — — .551
IrritabilityTreatment Group 1.19 — — .754
TimeIrritabilityTreatment Group 6.51 — — .688
Decomposing TimeTreatment Group Interaction
CC vs. MedMgt — L0.55 (L0.91 to L0.18) .003
CC vs. Beh — 0.24 (0.61 to 0.13) .198
CC vs. Comb — 0.30 (0.68 to 0.07) .111
MedMgt vs. Beh — 0.30 (0.05 to 0.66) .092
MedMgt vs. Comb — 0.24 (0.12 to 0.60) .185
Beh vs. Comb — 0.06 (0.05 to 0.66) .739
Decomposing IrritabilityTimeTreatment Group
Interaction
CC vs. MedMgt — 0.02 (0.05 to 0.09) .644
CC vs. Beh — 0.02 (0.05 to 0.10) .535
CC vs. Comb — 0.01 (0.09 to 0.06) .742
MedMgt vs. Beh — 0.01 (0.07 to 0.08) .853
MedMgt vs. Comb — 0.03 (0.10 to 0.04) .424
Beh vs. Comb — 0.04 (0.04 to 0.11) .346
Note: Significant results are shown in boldface. Beh ¼ behavioral treatment; CC ¼ community comparison; Comb ¼ combined treatment; MedMgt ¼ medication
management.
FIGURE S1 Path analyses of the relation between irritability and headstrong dimensions across time.
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